Search

Displaying results 4031 - 4040 of 10000 in total
  1. Drug

    SPP 301

    go.drugbank.com/drugs/DB05290
    Investigational

    SPP301 (Avosentan) is a potent and highly selective ET[A] receptor blocker and is clinically investigated in diabetic nephropathy.

  2. Drug

    Canfosfamide

    go.drugbank.com/drugs/DB04972
    Investigational

    Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.

  3. Drug

    alpha-Hydroxy glycineamide

    go.drugbank.com/drugs/DB06568
    Experimental

    It also has an effect on viral gp160 envelope protein. [A31692] … Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid

  4. Drug

    Zinc dibutyldithiocarbamate

    go.drugbank.com/drugs/DB14194
    Approved

    Zinc dibutyldithiocarbamate is a dermatological sensitizer and allergen. Sensitivity to zinc dibutyldithiocarbamate may be identified with a clinical patch test.

  5. Drug

    Lexibulin

    go.drugbank.com/drugs/DB05147
    Investigational

    CYT997 is an orally available vascular targeting and cytotoxic agent that has proven effective in animal models of a wide range of tumour types including breast, prostate and colon, as well as some leukemias

  6. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in

  7. Drug

    WX-UK1

    go.drugbank.com/drugs/DB05476
    Investigational

    Independent studies show that administration of Wx-UK1 resulted in a decrease of tumor cell invasion, suggesting its efficacy as a an adjuvant antimetastatic therapy of carcinomas. … a key role in metastasis and primary tumor growth of breast, gastric, colon cancer, and various other solid tumors.

  8. Drug

    ZYC300

    go.drugbank.com/drugs/DB04986
    Investigational

    It is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells. … ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles.

  9. Drug

    Bepotastine

    go.drugbank.com/drugs/DB04890
    Approved

    Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the … It is available in oral and opthalmic dosage forms in Japan. The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve.

  10. Drug

    Zolasartan

    go.drugbank.com/drugs/DB20140
    Experimental

    The usage of the INN stem '-sartan' in the name indicates that Zolasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

    Categories: Agents Acting on the Renin-Angiotensin System